Compare BKTI & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BKTI | VNDA |
|---|---|---|
| Founded | 1997 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 244.2M | 289.0M |
| IPO Year | N/A | 2006 |
| Metric | BKTI | VNDA |
|---|---|---|
| Price | $66.17 | $5.76 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $74.00 | $14.00 |
| AVG Volume (30 Days) | 50.5K | ★ 874.6K |
| Earning Date | 11-06-2025 | 10-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 136.69 | N/A |
| EPS | ★ 3.30 | N/A |
| Revenue | $82,558,000.00 | ★ $212,074,000.00 |
| Revenue This Year | $11.20 | $12.01 |
| Revenue Next Year | $10.66 | $21.57 |
| P/E Ratio | $20.00 | ★ N/A |
| Revenue Growth | 10.12 | ★ 11.12 |
| 52 Week Low | $26.20 | $3.81 |
| 52 Week High | $86.24 | $5.70 |
| Indicator | BKTI | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 45.63 | 63.01 |
| Support Level | $61.94 | $4.89 |
| Resistance Level | $66.72 | $5.36 |
| Average True Range (ATR) | 3.78 | 0.31 |
| MACD | 0.12 | 0.08 |
| Stochastic Oscillator | 56.46 | 89.31 |
BK Technologies Corp a holding company, operates through its subsidiary, BK Technologies, Inc., specializing in designing, manufacturing, and marketing wireless communications equipment. Its Radio business unit offers two-way land mobile radios (LMRs) serving government and public safety markets, as well as industrial and commercial enterprises. The SaaS business unit focuses on public safety smartphone applications, enhancing first responders' safety and efficiency. The BKRplay application, tethered to BK radios, amplifies user capabilities, expanding the reach of their radio sales. Its product portfolio consists of two-way land mobile radios, handheld radios, radios installed in vehicles.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.